Table 1. The 16 IGF-1R Inhibitors and the Estimated Number of Patients Entered Into Clinical Trialsa.
| Drug name | IGF-1R inhibitor type | Company | Estimated No. of patients |
|---|---|---|---|
| AMG479 (ganitumab) | Antibody | Amgen/NantCell | 2864 |
| AVE1642 | Antibody | Sanofi-Aventis | 57 |
| AXL1717 | Small molecule | Axelar AB | 204 |
| BIIB022 | Antibody | Biogen Idec | 98 |
| BMS-754807 | Small molecule | Bristol-Myers Squibb | 296 |
| CP-751 871 (figitumumab) | Antibody | Pfizer | 2029 |
| IGV-001 | Antisense/cell therapy | Imvax | 93 |
| IMCA12 (cixutumumab) | Antibody | Eli Lilly and Company/NCI | 2791 |
| KW-2450 | Small molecule | Kyowa Hakko Kirin Pharma Inc | 83 |
| MK7454 (robatumumab) | Antibody | Merck & Co/Schering Plough | 305 |
| MK0646 (dalotuzumab) | Antibody | Merck, Sharpe & Dohme Corp | 1436 |
| MM141 (istiratumab) | Antibody | Merrimack Pharmaceuticals | 135 |
| OSI906 (linsitinib) | Small molecule | Oncogene Sciences/Astellas Pharma Inc | 1277 |
| PL225B | Small molecule | Piramal Enterprises Ltd | 70 |
| RG1507 (teprotumumab) | Antibody | Hoffmann-La Roche | 525b |
| XL228 | Small molecule | Exelixis | 133 |
Abbreviations: IGF-1R, insulin-like growth factor-1 receptor; NCI, National Cancer Institute.
a
The estimated number of patients in trial programs with data taken from eTables 1 and 2 in Supplement 2.
b
Oncology only, subsequently developed for Graves disease by Horizon.15